



(51) International Patent Classification:

A61P 19/04 (2006.01) A61J 1/22 (2006.01)
A61K 33/30 (2006.01) A61M 3/00 (2006.01)
A61K 9/08 (2006.01) A61M 5/178 (2006.01)
A61P 19/00 (2006.01)

(21) International Application Number:

PCT/US2016/042531

(22) International Filing Date:

15 July 2016 (15.07.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/193,476 16 July 2015 (16.07.2015) US

(71) Applicant: **MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH** [US/US]; 200 First Street S.W., Rochester, Minnesota 55905 (US).

(72) Inventors: **RIESTER, Scott M.**; 925 41st Street N.W., Apt. 107, Rochester, Minnesota 55901-4266 (US). **SPERLING, John W.**; 835 Fox Pointe Lane S.W., Rochester, Minnesota 55902 (US). **VAN WIJNEN, Andre J.**; 2717 Headland Court S.W., Unit 3224, Rochester, Minnesota 55902 (US).

(74) Agent: **FINN, J., Patrick, III**; Fish & Richardson P.C., PO Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))



WO 2017/011762 A1

(54) Title: TREATING ROTATOR CUFF CONDITIONS

(57) Abstract: This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears). For example, methods and materials for using zinc or a zinc chelator to treat rotator cuff conditions are provided.

TREATING ROTATOR CUFF CONDITIONS

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Application Serial No. 62/193,476, filed on July 16, 2015. The disclosure of the prior application is considered part of the disclosure of this application, and is incorporated in its entirety into this application.

BACKGROUND

1. Technical Field

This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial or complete rotator cuff tears). For example, this document provides methods and materials for modulating zinc homeostasis using zinc or zinc chelators to treat rotator cuff conditions.

15

2. Background Information

The rotator cuff is a group of muscles and tendons that surround the shoulder joint, keeping the head of your upper arm bone firmly within the shallow socket of the shoulder. A rotator cuff injury can cause pain as well as loss of shoulder function.

20

SUMMARY

This document provides methods and materials related to treating rotator cuff conditions (e.g., rotator cuff tendonitis or rotator cuff injuries such as partial or complete rotator cuff tears). For example, this document provides methods and materials for modulating zinc homeostasis using zinc or zinc chelators to treat rotator cuff conditions. In some cases, a composition that includes zinc or one or more zinc chelators can be administered to (e.g., injected or infused into) the rotator cuff region of a mammal suffering from a rotator cuff condition. In some cases, a composition that includes zinc can be introduced at the time of a surgical repair. In such cases, the administered (e.g., injected) composition can reduce or reverse tendon degeneration, enhance healing, and/or increase tendon strength.

25
30

This document also provides methods and materials for using zinc or one or more zinc chelators to reduce the risk of developing a rotator cuff condition or to slow

the progression of a rotator cuff condition. In some cases, a composition that includes zinc can be administered to (e.g., injected or infused into) the rotator cuff region of a mammal identified as being likely to develop a rotator cuff condition. In such cases, the administered (e.g., injected or infused) composition can prevent or slow the
5 development of a rotator cuff condition.

In some cases, zinc or a zinc-chelator can be used alone or in conjunction with growth factors (e.g., FGFs or BMPs), epigenetic inhibitors (e.g., HDACs, SIRT6, and EZH2 inhibitors) other metals (e.g., Mg, Ca, or Se), or biomaterials (e.g., for controlled release of zinc) to treat a rotator cuff condition or to prevent or slow the
10 development of a rotator cuff condition. For example, zinc or a zinc-chelator can be combined with one or more bioactive molecules as a solution or as part of a biocompatible scaffold or carrier to form a composition that is used to treat a mammal suffering from a rotator cuff condition.

In general, one aspect of this document features a method for treating a
15 mammal having a rotator cuff condition. The method comprises, or consisting essentially of, administering a composition comprising, or consisting essentially of, zinc or a zinc chelator into a rotator cuff region of the mammal, wherein administration of the composition reduces or reverses tendon degeneration, enhances tendon healing, or increases tendon strength. The mammal can be a human. The
20 rotator cuff condition can be a rotator cuff condition wherein a rotator cuff tendon is partially torn. The rotator cuff condition can be a rotator cuff condition wherein a rotator cuff tendon is ruptured. The rotator cuff condition can be rotator cuff tendonitis. The administering step can be an intra-articular injection into a joint space. The administering step can be an injection into a subacromial space. The
25 administering step can be a direct injection into a damaged tendon. The composition can comprise zinc, wherein the zinc is ZnCl₂, zinc sulfate, zinc picolinate, zinc citrate, zinc glycerate, zinc gluconate, zinc acetate, or zinc monomethionine. The composition can comprise a zinc chelator. The composition can be housed within a device that controls the release of the composition within the mammal.

30 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and

other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

5 The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the invention will be apparent from the description and from the claims.

DETAILED DESCRIPTION

10 This document provides methods and materials related to using zinc or one or more zinc chelators to treat rotator cuff conditions or to prevent or slow the development of rotator cuff conditions. For example, a composition that includes zinc can be administered to (e.g., injected or infused into) the rotator cuff region of a mammal suffering from a rotator cuff condition or identified as being likely to
15 develop a rotator cuff condition. In such cases, the administered (e.g., injected or infused) composition can reduce or reverse tendon degeneration, enhance healing, increase tendon strength, and/or prevent or slow the development of a rotator cuff condition. Examples of different forms of zinc that can be used as described herein include, without limitation, ZnCl, zinc sulfate, zinc picolinate, zinc citrate, zinc
20 glycerate, zinc gluconate, zinc acetate, and zinc monomethionine. Examples of zinc chelators that can be used as described herein include, without limitation, N,N,N',N'-tetrakis-(2-pyridylmethyl) ethylenediamine (TPEN), phenanthroline, EDTA, and EGTA.

 Any appropriate rotator cuff condition can be treated as described herein. For
25 example, rotator cuff tendonitis or rotator cuff injuries such as partial rotator cuff tears or rotator cuff ruptures can be treated as described herein. In addition, any appropriate mammal can be treated using the methods and materials described herein. For example, humans, monkeys, dogs, horses, sheep, pigs, goats, rabbits, rats or mice can be treated as described herein.

30 In some cases, a composition that includes zinc or one or more zinc chelators can be administered to a mammal by injecting or infusing the composition into the rotator cuff region of a mammal. For example, an injectable solution containing zinc or one or more zinc chelators can be injected into the rotator cuff region of a human suffering from a rotator cuff condition or identified as being likely to develop a rotator

cuff condition. When injecting or infusing a composition that includes zinc or one or more zinc chelators into tissue of a mammal (e.g., a human), the composition can include a hydrogel, an aqueous solution, or ingredients that generate an isotonic solution (e.g., saline), or can be attached to an organic scaffold. The composition can
5 have a pH that is at or near a physiological neutral pH (e.g., pH 6-8). In some cases, zinc, for example, in the form of ZnCl or ZnSO₄, a chelated form of zinc, and/or a zinc chelator can be formulated into a composition for injection or infusion into the rotator cuff region of a mammal.

A composition provided herein (e.g., a composition containing zinc or a zinc
10 chelator) can be administered to a rotator cuff region of a mammal by intra-articular injection into the joint space, injection into the subacromial space, direct injection into damaged tendons, delivery as a topical at the time of surgical repair that could include delivery to the tendon itself, delivery to the bone tendon interface, or delivery directly into the joint space. In some cases, a composition provided herein (e.g., a
15 composition containing zinc or a zinc chelator) can be administered to a rotator cuff region of a mammal using a suture coated with or containing zinc or a zinc chelator placed into the joint, adjacent to the tendon, or at the bone tendon interface.

In some cases, a composition that includes zinc or a zinc chelator can be administered to a mammal orally, topically, or systemically (e.g., intravenously, via
20 general injection, or intranasally via a nasal spray). For example, a pill or capsule containing zinc can be orally administered to a human suffering from a rotator cuff condition or identified as being likely to develop a rotator cuff condition. When administering a composition that includes zinc orally to a mammal (e.g., a human), the composition can include zinc sulfate, zinc picolinate, zinc citrate, zinc glycerate,
25 zinc gluconate, zinc acetate, or zinc monomethionine.

In some cases, a composition that includes zinc or a zinc chelator can include zinc or the zinc chelator as the sole active ingredient or can include other active ingredients for treating rotator cuff conditions. For example, a composition that includes zinc or a zinc chelator can include growth factors (e.g., FGFs or BMPs),
30 epigenetic inhibitors (e.g., HDACs, SIRTs, or EZH2 inhibitors), minerals (e.g., Mg, Ca, or Se), biomaterials (e.g., biomaterials for controlled release of zinc), stem cells (e.g., bone marrow derived or adipose-tissue derived stem cells), or combinations thereof as active ingredients for treating a rotator cuff condition.

An effective amount of a composition containing zinc can be any amount that

reduces the severity of a symptom of a condition being treated (e.g., a rotator cuff condition), reduces the risk of developing a rotator cuff condition, or slows the progression of a rotator cuff condition without producing significant toxicity to the mammal. For example, an effective amount of zinc can be from about 0.1 pM to
5 about 100 mM (e.g., from about 100 pM to about 100 mM, from about 10 nM to about 100 mM, from about 1 mM to about 100 mM, from about 1 nM to about 10 mM, or from about 10 nM to about 1 mM). In some cases, between about 1 fg and about 2 mg of zinc can be administered to an average sized human (e.g., about 60-85 kg human) daily for about four to about eight weeks (e.g., about five to six weeks). If
10 a particular mammal fails to respond to a particular amount, then the amount of zinc can be increased by, for example, two fold. After receiving this higher amount, the mammal can be monitored for both responsiveness to the treatment and toxicity symptoms, and adjustments made accordingly. The effective amount can remain constant or can be adjusted as a sliding scale or variable dose depending on the
15 mammal's response to treatment. Various factors can influence the actual effective amount used for a particular application. For example, the frequency of administration, duration of treatment, use of multiple treatment agents, route of administration, and severity of the condition (e.g., rotator cuff condition) may require an increase or decrease in the actual effective amount administered.

20 The frequency of administration can be any frequency that reduces the severity of a symptom of a condition to be treated (e.g., a rotator cuff condition), reduces the risk of developing a rotator cuff condition, or slows the progression of a rotator cuff condition without producing significant toxicity to the mammal. For example, the frequency of administration can be from about three times a day to about
25 once a month. In some cases, a one-time administration (e.g., before, during, or after surgery) can be administered. The frequency of administration can remain constant or can be variable during the duration of treatment. In some cases, zinc can be administered using a continual slow release from a device (e.g., a scaffold) placed into the mammal (e.g., a human) during surgery. A course of treatment with a
30 composition containing zinc can include rest periods. For example, a composition containing zinc can be administered daily over a two week period followed by a two week rest period, and such a regimen can be repeated multiple times. As with the effective amount, various factors can influence the actual frequency of administration used for a particular application. For example, the effective amount, duration of

treatment, use of multiple treatment agents, route of administration, and severity of the condition (e.g., a rotator cuff condition) may require an increase or decrease in administration frequency.

5 An effective duration for administering a composition containing zinc can be any duration that reduces the severity of a symptom of the condition to be treated (e.g., a rotator cuff condition), reduces the risk of developing a rotator cuff condition, or slows the progression of a rotator cuff condition without producing significant toxicity to the mammal. Thus, the effective duration can vary from several days to several weeks, months, or years. In general, the effective duration for the treatment of
 10 a rotator cuff condition can range in duration from several weeks to the mammal's lifetime. Multiple factors can influence the actual effective duration used for a particular treatment. For example, an effective duration can vary with the frequency of administration, effective amount, use of multiple treatment agents, route of administration, and severity of the condition being treated.

15 In some cases, the methods and materials provided herein (e.g., a composition containing zinc) can be used to treat tendonitis or a tendon disorder such as an Achilles tendon disorder, a patellar tendon disorder, a quadriceps tendon disorder, or an epicondylitis.

20 The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1 – Assessment of damaged/ruptured rotator cuff tendons

25 High throughput RNA-sequencing of intact and ruptured rotator cuff tendons was performed. The sequencing analysis revealed that degenerating rotator cuff tissue exhibit changes in the expression levels of many zinc-related polypeptides (Table 1).

Table 1. Expression of zinc-related genes in rotator cuff tendon.

Gene	Fold Change Intact vs Diseased Tendon
ZNF131	7.74495203
ZNF224	7.7104387
ZNF354C	7.33998444
ZNF718	7.23646262
MT1B	0.121312
CRIP2	0.180982

CRIP1	0.086645
MT3	0.00438
MT1H	0.096981

These results demonstrate that zinc deficiency and concomitant oxidative responses are involved in rotator cuff degeneration. These results also demonstrate that zinc supplementation (via oral administration or injection or infusion into rotator cuff tissue) can mitigate or reverse rotator cuff degeneration and associated pathological conditions (e.g., rotator cuff tears and tendonopathy).

Example 2 – Injecting zinc to treat damaged/ruptured rotator cuff tendons

About 1-2 mg of zinc is formulated with 1 to 10 mL of saline or other soluble solution to obtain a liquid composition. About 0.25 mL to about 1 mL of this liquid composition is injected directly into degenerative or surgically repaired tendons or into the joint space to deliver zinc to the target tissue.

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A method for treating a mammal having a rotator cuff condition, wherein said method comprising administering a composition comprising zinc or a zinc chelator into a rotator cuff region of said mammal, wherein administration of said composition reduces or reverses tendon degeneration, enhances tendon healing, or increases tendon strength.
2. The method of claim 1, wherein said mammal is a human.
3. The method of claim 1, wherein said rotator cuff condition is a rotator cuff condition wherein a rotator cuff tendon is partially torn.
4. The method of claim 1, wherein said rotator cuff condition is a rotator cuff condition wherein a rotator cuff tendon is ruptured.
5. The method of claim 1, wherein said rotator cuff condition is rotator cuff tendonitis.
6. The method of claim 1, wherein said administering step is an intra-articular injection into a joint space.
7. The method of claim 1, wherein said administering step is an injection into a subacromial space.
8. The method of claim 1, wherein said administering step is a direct injection into a damaged tendon.
9. The method of claim 1, wherein said composition comprises zinc, and wherein said zinc is ZnCl, zinc sulfate, zinc picolinate, zinc citrate, zinc glycerate, zinc gluconate, zinc acetate, or zinc monomethionine.
10. The method of claim 1, wherein said composition comprises a zinc chelator.

11. The method of claim 1, wherein said composition is housed within a device that controls the release of said composition within said mammal.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 16/42531

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - A61P 19/04; A61K 33/30; A61K 9/08; A61P 19/00; A61J 1/22; A61M 3/00; A61M 5/178 (2016.01)
CPC - A61L 2430/10; A61K 33/30; A61K 31/198; A61K 9/0019; A61M 5/178
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
IPC(8) - A61P 19/04; A61K 33/30; A61K 9/08; A61P 19/00; A61J 1/22; A61M 3/00; A61M 5/178 (2016.01)
CPC - A61L 2430/10; A61K 33/30; A61K 31/198; A61K 9/0019; A61M 5/178

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
 Patents and non-patent literature (classification, keyword; search terms below)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 PatBase, Google Scholar (NPL), Google Patents; search terms: method, treating, rotator cuff condition, administer, inject, tendon, torn, ruptured, tendonitis, intra-articular injection, joint space, subacromial space, zinc, Zn, ZnCl, zinc sulfate, zinc citrate, zinc chelator, housing, device, controls release, mammal, human

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2012/0328700 A1 (HILL et al.) 27 December 2012 (27.12.2012) para [0002], [0008]-[0009], [0018]-[0020], [0025], [0071], [0073], [0128]-[0133], [0136]-[0137]	1-11
A	Simons et al., "Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)" (18 July 2013) [online] [retrieved on 15 September 2016]. Retrieved from the Internet <URL: http://web.archive.org/web/20130718152310/http://www.uptodate.com/contents/rotator-cuff-tendinitis-and-tear-beyond-the-basics?view=print > pg 1-2	5
A	Caring Medical Regenerative Medicine Clinics, "Prolotherapy" (12 April 2015) [online] [retrieved on 15 September 2016]. Retrieved from the Internet <URL: http://web.archive.org/web/20150412171914/http://www.caringmedical.com/prolotherapy/ > entire document	1-11
A	Caring Medical Regenerative Medicine Clinics, "Prolotherapy for shoulder pain" (18 October 2011) [online] [retrieved on 15 September 2016]. Retrieved from the Internet <URL: https://www.youtube.com/watch?v=eXl3cJQQKUA > entire document	1-11
A	Deborah Gordon, "Rotator Cuff Injury and Regenerative Injection Therapy" (06 January 2013) [online] [retrieved on 15 September 2016]. Retrieved from the Internet <URL: http://www.drdeborahmd.com/rotator-cuff-injury-and-regenerative-injection-therapy > entire document	1-11
A	Wellmark, "Prolotherapy" [online] (26 May 2015) [retrieved on 15 September 2016]. Retrieved from the Internet <URL: http://web.archive.org/web/20150526114740/http://www.wellmark.com/Provider/MedpoliciesAndAuthorizations/MedicalPolicies/policies/Prolotherapy.aspx > entire document	1-11

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 15 September 2016	Date of mailing of the international search report 13 OCT 2016
--	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774
---	--